Table 5.
Postneonatal outcomes of children exposed to chemotherapy in utero
| Reported outcome | n / N (%) | ≥4 cycles of anthracycline-based in utero chemotherapy exposure, n / N (%) | Population prevalence, % [reference] |
|---|---|---|---|
| Child considered healthy | 49/50 (98) | – | – |
| Developmental milestone delays | 6/50 (12) | 2/6 (33) | 10 [22] |
| Difficulties in schoola | 4/37 (11) | 3/4 (75) | 6-11 [22] |
| Reported health concerns | 31/50 (62) | 19/31 (61) | – |
| Allergies/eczema | 18/50 (36) | 12/18 (67) | 11 to 25 [22] |
| Asthma/breathing | 5/50 (10) | 4/5 (80) | 13 [22] |
| Vision | 8/50 (16) | 5/8 (63) | 14 [22] |
| Heart murmurb | 1/50 (2) | – | 1.3 [23] |
| “Lazy eye” | 2/50 (4) | 1/2 (50) | 1.6 to 3.6 [24] |
| Absence seizuresc | 1/50 (2) | 1/1 (100) | <1 [25] |
| ENTd | 4/50 (8) | 3/4 (75) | HL, <1; ROM, 18 to 26d [26] |
| GERDe | 2/50 (6) | 2/2 (100) | 5 to 67f [27] |
aReading delay (n = 3) and difficulty with attention span (n = 1); data are for 37 school-aged children. bResolved by age 1 year. cPossibly hereditary. dEar, nose, and throat (ENT) includes recurrent otitis media (ROM; n = 2), sinus problems (n = 1) and hearing deficit (HL; n = 1). eGastroesophageal reflux disease. fVaries according to age.